Analysen von Nicolas Guyon-Gellin

09.02.17 GSK Equal-Weight Morgan Stanley
06.02.17 GSK Equal-Weight Morgan Stanley
18.01.17 AstraZeneca overweight Morgan Stanley
04.11.16 Novo Nordisk Equal-Weight Morgan Stanley
02.11.16 AstraZeneca overweight Morgan Stanley
31.10.16 Novo Nordisk Equal-Weight Morgan Stanley
19.08.16 AstraZeneca overweight Morgan Stanley
13.07.16 Novo Nordisk overweight Morgan Stanley
11.07.16 GSK Equal-Weight Morgan Stanley
09.06.16 Novo Nordisk overweight Morgan Stanley
31.05.16 GSK Equal-Weight Morgan Stanley
28.04.16 GSK Equal-Weight Morgan Stanley
22.04.16 Novo Nordisk overweight Morgan Stanley
20.04.16 GSK Equal-Weight Morgan Stanley
22.03.16 Novo Nordisk overweight Morgan Stanley
09.03.16 AstraZeneca overweight Morgan Stanley
07.03.16 Novo Nordisk overweight Morgan Stanley
04.02.16 GSK Equal-Weight Morgan Stanley
01.02.16 Novo Nordisk overweight Morgan Stanley
06.01.16 Novo Nordisk overweight Morgan Stanley
18.12.15 AstraZeneca overweight Morgan Stanley
03.12.15 AstraZeneca overweight Morgan Stanley
03.12.15 AstraZeneca overweight Morgan Stanley
06.11.15 GSK Equal-Weight Morgan Stanley
05.11.15 GSK Equal-Weight Morgan Stanley
22.10.15 AstraZeneca Underweight Morgan Stanley
21.10.15 GSK Equal-Weight Morgan Stanley
19.08.15 AstraZeneca Underweight Morgan Stanley
30.07.15 GSK Equal-Weight Morgan Stanley
24.07.15 AstraZeneca Underweight Morgan Stanley
04.06.15 GSK Equal-Weight Morgan Stanley
05.05.15 GSK overweight Morgan Stanley
08.04.15 AstraZeneca verkaufen Morgan Stanley
18.03.15 GSK overweight Morgan Stanley
03.12.14 AstraZeneca Underweight Morgan Stanley
23.10.14 GSK overweight Morgan Stanley
29.09.14 AstraZeneca Equal-Weight Morgan Stanley
15.05.14 GSK overweight Morgan Stanley
21.12.12 H. Lundbeck A-S kaufen Exane-BNP Paribas SA
19.12.12 Actelion outperform Exane-BNP Paribas SA
19.12.12 Shire outperform Exane-BNP Paribas SA
20.11.12 Novartis outperform Exane-BNP Paribas SA
19.11.12 Merck neutral Exane-BNP Paribas SA
09.11.12 Merck neutral Exane-BNP Paribas SA
26.10.12 Shire outperform Exane-BNP Paribas SA
25.10.12 Ipsen neutral Exane-BNP Paribas SA
23.10.12 Elan neutral Exane-BNP Paribas SA
17.10.12 Roche outperform Exane-BNP Paribas SA